MRM Health NV is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome.The company is based in a Center of Expertise for microbiome research and development in the biotech cluster in Ghent, Belgium, and has a strategic partnership with the VIB, with top research groups in both microbiome analysis and ecology and in host biology and disease research. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB and has a corporate collaboration with DuPont Nutrition Biosciences in the development of microbiome-based therapeutics for metabolic diseases.
MRM Health's proprietary technology platform brings live microbial therapeutics development to the next level by combining rationally selected strains into synergistic consortia through a proprietary optimization process.
MRM Health's proprietary technology platform brings live microbial therapeutics development to the next level by combining rationally selected strains into synergistic consortia through a proprietary optimization process.
Location: Belgium
Employees: 11-50
Phone: +91 86778 68013
Total raised: $64.32M
Founded date: 2020
Investors 2
| Date | Name | Website |
| 23.09.2025 | SFPIM | sfpim.be |
| - | KU Leuven ... | lrd.kuleuv... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.09.2025 | Series B | $64.32M | SFPIM |
Mentions in press and media 7
| Date | Title | Description |
| 12.09.2025 | MRM Health: €55 Million Series B Raised For Microbiome-Based Drug Candidates | MRM Health has completed a €55 million Series B financing round that will enable the company to push its microbiome-based drug candidates through critical development milestones and broaden its pipeline of live biotherapeutic products. Bioc... |
| 07.09.2025 | Belgian Biopharma MRM Health Secures €55 Million to Drive Microbiome Therapeutic Innovation | MRM Health, a Belgian biopharma, closed a €55 million Series B financing round. This capital accelerates groundbreaking microbiome-based therapeutics. Lead program MH002 targets ulcerative colitis, entering Phase 2b trials. The proprietary ... |
| 04.09.2025 | MRM Health Raises €55 Million Series B | Ghent, Belgium – September 04, 2025 – MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million ... |
| 04.09.2025 | Belgium’s MRM Health raises €55 million for microbiome-based biotherapeutic product pipeline | MRM Health, a Ghent-based clinical-stage biopharmaceutical company developing microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million Series B financing round. The... |
| 10.09.2024 | MRM Health appoints Grégoire Franoux as Chief Business Officer and adds Ron Robison to its Board of Directors | GHENT, Belgium, September 10, 2024 – MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced the appointment of Grégoire Franoux, M.B.A., to ... |
| 25.03.2022 | Qbic establishes third fund | St-Denijs-Westrem, Belgium, 17 March 2022 – Qbic, an inter-university venture capital fund focusing on the transformation of technological breakthroughs into sustainable businesses, announces the first close of its third fund at € 49 millio... |
| - | MRM Health NV | “Redefining microbiome-based therapeutics” |